Intervention Study for the effect of Istradefylline on onset of Dyskinesia in Patients with Parkinson's Disease (ODYSSEI Study)

未提供0 个研究点目标入组 280 人开始时间: 2017年3月8日最近更新: 2024年7月1日

适应症

试验速览

暂无简介。

•Current use of levodopa-containing drugs more than 300mg/day administered at least three times daily
•Patients with wearing-off
•Patients who have never previously experienced dyskinesia
•>= 30 to < 80 years of age at the time of consent.
•Diagnosed as Parkinson's disease based on UK Parkinson's Disease Society Brain Bank criteria
•Stages <=4 in the ON state for Modified Hoehn and Yahr Scale.
•Stable antiparkinson drug regimen for at least 4 weeks prior to study entry.
•Completion of patient diary training and able to satisfactorily complete patient diary.
•Patients who have given written consent if the patient has difficulty in writing due to his or her condition, a representative may sign the written consent, subject to the patient's prior oral consent

•Current use of Istradefylline (within 1 year prior to study entry)
•Current use of amantadine (within 3 months prior to study entry)
•Current use of an investigational drug (within 4 months prior to study entry.)
•Patients with dementia or a score of 23 or less on the Mini-Mental State Examination (MMSE)
•Patients with a previous history of brain surgery for the treatment of parkinson's disease.
•Current use or plan to administer levodopa/carbidopa intestinal gel
•Patients with moderate to severe hepatic disorder
•Current use of a strong inhibitor of CYP3A4 (within 14days prior to study entry)
•Current use of typical and atypical antipsychotics (within 3 months prior to study entry)
•Female patients who are pregnant, trying to become pregnant or nursing (lactating) an infant.
•Patients who are in the Investigator's judgment unlikely to comply with medical regimens or study requirements.

Time to onset of dyskinesia

未报告次要终点

发起方

未提供